Search Results

Coriolis Pharma, a globally operating service provider for R&D and GMP drug product development, R&D and GMP analytics and sterile drug product manufacturing support, announced the launch of a U.S. entity that allows customers to combine the convenience of a local service with the advantages of international expertise.

An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.

Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, received CDMO Leadership Awards in all six categories - Capabilities, Compatibility, Expertise, Quality, Reliability, and Service for both the Overall and Big Pharma respondent groups.

Imagine Pharma, a biotech company focused on advancing the commercialization of its novel IMG-1 polypeptide in Oral Delivery, Therapeutics, and Regenerative Medicine, announced that the West Virginia University Health System, which operates under the brand WVU Medicine, has awarded a contract to the Company to provide human clinical islet isolation services for patients undergoing a total pancreatectomy and autologous islet cell transplant.

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that Ayana Pharma Ltd. signed a five-year Master Service Agreement (MSA) with the Company’s CDMO business unit, Scinai Bioservices.

Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.

Not all licensing deals are successful. Here, BioSpace examines a few noteworthy assets that Big Pharma returned in the last 12 months.

FSD Pharma Inc. is pleased to announce that it has entered into an investor relations services agreement with IR Agency LLC effective May 22, 2024.

Alcami Corporation announced the opening of its new 65,000 ft² state-of-the-art Pharma Storage and Services operations facility in Garner, North Carolina close to the Research Triangle Park biotech and pharma hub.

LGM Pharma announced a significant enhancement of its capabilities: a 50% expansion and an investment exceeding $2 million in its standalone offering for Analytical Testing Services alongside the introduction of new suppository manufacturing capabilities to its contract development and manufacturing portfolio.